Final analysis of a phase II trial of daratumumab, carfilzomib, lenalidomide, and dexamethasone in newly diagnosed multiple myeloma without transplant - Top-Institutions - MDSpire

Final analysis of a phase II trial of daratumumab, carfilzomib, lenalidomide, and dexamethasone in newly diagnosed multiple myeloma without transplant

  • By

  • Benjamin A. Derman

  • Jennifer Cooperrider

  • Jacalyn Rosenblatt

  • David E. Avigan

  • Murtuza Rampurwala

  • David Barnidge

  • Ajay Major

  • Theodore Karrison

  • Ken Jiang

  • Aubrianna Ramsland

  • Tadeusz Kubicki

  • Andrzej J. Jakubowiak

  • May 29, 2024

  • 0 min

Share

Top Institutions in Hematology

Brief introduction explaining scope and methodology.

  • #1

    Dana-Farber Cancer Institute
    Dana-Farber Cancer Institute

    Boston, MA

    Key Differentiators

    • Hematology
    • Oncology
    • Multiple Myeloma Research

  • #2

    Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer Center

    New York, NY

    Key Differentiators

    • Hematology
    • Oncology
    • Multiple Myeloma

  • #3

    Mayo Clinic
    Mayo Clinic

    Rochester, MN

    Key Differentiators

    • Hematology
    • Oncology
    • Multiple Myeloma

  • #4

    University of Arkansas for Medical Sciences (UAMS)
    University of Arkansas for Medical Sciences (UAMS)

    Little Rock, AR

    Key Differentiators

    • Hematology
    • Oncology
    • Multiple Myeloma

  • #5

    Johns Hopkins University
    Johns Hopkins University

    Baltimore, MD

    Key Differentiators

    • Hematology
    • Oncology
    • Multiple Myeloma

Original Source(s)

Final analysis of a phase II trial of daratumumab, carfilzomib, lenalidomide, and dexamethasone in newly diagnosed multiple myeloma without transplant

  • by Benjamin A. Derman, Jennifer Cooperrider, Jacalyn Rosenblatt, David E. Avigan, Murtuza Rampurwala, David Barnidge, Ajay Major, Theodore Karrison, Ken Jiang, Aubrianna Ramsland, Tadeusz Kubicki, Andrzej J. Jakubowiak

  • May 29, 2024

Related Content

Short-term cardiotoxicity and early echocardiographic changes following autologous hematopoietic stem cell transplantation: a single-center retrospective analysis

This Week’s CGT News: Lilly’s $7B In Vivo CAR-T Bet

Lilly moves to acquire Kelonia, plus gene therapy for deafness approved

  • April 27, 2026

  • 6 min
Not all plasma cells are made equal: well-hidden layers of heterogeneity